StoxOnesource Specialty Pharma vs Concord Biotech: share price & financials comparison
NSE: ONESOURCE vs CONCORDBIO · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Onesource Specialty Pharma vs Concord Biotech at a glance
Onesource Specialty Pharma (ONESOURCE) has a market capitalisation of ₹18,463 Cr, against ₹6,214 Cr for Concord Biotech (CONCORDBIO). Over the past year Onesource Specialty Pharma has returned -12.2%, compared with -18.3% for Concord Biotech. Concord Biotech earns a higher return on equity (13.6% vs -0.0%). Onesource Specialty Pharma comes out ahead on growth, momentum and technicals. Concord Biotech comes out ahead on size, valuation and profitability. Across the scored metrics below, Onesource Specialty Pharma leads on 6 and Concord Biotech on 5. On StoxGud's 10-point checklist, Onesource Specialty Pharma scores 4/10 and Concord Biotech scores 6/10.
| Metric | Onesource Specialty Pharma | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹18,463 Cr | ₹6,214 Cr |
| Revenue (latest FY) | ₹1,422 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹-74 Cr | ₹261 Cr |
| Valuation | ||
| P/E | — | 22.0 |
| P/B | 3.12 | 2.99 |
| Dividend yield | — | 1.80% |
| Profitability | ||
| Return on equity | 0.0% | 13.6% |
| Net profit margin | -0.1% | 24.1% |
| Operating margin | 23.5% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | +37.4% | +25.1% |
| Net profit growth (YoY) | +687.0% | +11.1% |
| Revenue CAGR (multi-year) | — | +1.8% |
| Financial health | ||
| Debt to equity | 0.25 | 0.00 |
| Momentum | ||
| 1-month return | +10.3% | -13.3% |
| 1-year return | -12.2% | -18.3% |
| 3-year CAGR | — | -3.0% |
| Distance from 52W high | -13.8% | -25.2% |
| Technicals | ||
| RSI (14) | 82 | 47 |
| Price vs 200-day avg | +4.0% | -6.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Onesource Specialty Pharma | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 4/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Onesource Specialty Pharma or Concord Biotech?
Onesource Specialty Pharma has a market cap of ₹18,463 Cr and Concord Biotech has a market cap of ₹6,214 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Onesource Specialty Pharma or Concord Biotech?
Onesource Specialty Pharma did better: Onesource Specialty Pharma returned -12.2% and Concord Biotech returned -18.3% over one year.
What is the difference between Onesource Specialty Pharma and Concord Biotech?
Both are NSE-listed companies in Healthcare. Onesource Specialty Pharma is about 3.0 times the size of Concord Biotech by market cap. In the latest financial year Onesource Specialty Pharma reported revenue of ₹1,422 Cr and Concord Biotech ₹1,055 Cr. Operating margin is 23.5% for Onesource Specialty Pharma and 34.5% for Concord Biotech. Debt to equity is 0.25 for Onesource Specialty Pharma and 0.00 for Concord Biotech.
Which is better, Onesource Specialty Pharma or Concord Biotech?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Onesource Specialty Pharma leads on 6 and Concord Biotech on 5. Onesource Specialty Pharma is ahead on growth, momentum and technicals. Concord Biotech is ahead on size, valuation and profitability. On StoxGud's rules-based checklist Onesource Specialty Pharma scores 4/10 and Concord Biotech scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.